MedTrace Logo

Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer

NCT05976932 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-08-04

No results posted yet for this study

Summary

This observational study is conducted to assess the utility of circulating tumor DNA in monitoring the response to pegylated liposomal doxorubicin in platinum-resistant ovarian cancer，and evaluate the consistency of circulating tumor DNA with imaging and CA125 in platinum-resistant ovarian cancer.

Conditions

Interventions

DRUG

pegylated liposomal doxorubicin

All eligible subjects will receive the standard chemotherapy of pegylated liposomal doxorubicin monotherapy.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2024-04-30
Completion
2024-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05976932 on ClinicalTrials.gov